Aceragen acquires Enzyvant’s investigational therapy to treat Farber disease
The investigational therapy has been designed to address the genetic deficiency of the naturally occurring enzyme which is…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 May 21
The investigational therapy has been designed to address the genetic deficiency of the naturally occurring enzyme which is…
12 Apr 21
With the acquisition, Sanofi is expected to benefit from a new technology platform that expands its research capabilities…
22 Mar 21
The new Covid-19 vaccine candidate is a virus like particle (VLP) triple antigen vaccine, which offers triple protection…
29 Dec 20
The generic glucagon is a synthetic version of human glucagon, a hormone that causes the liver to increase…
09 Nov 20
The acquisition will help Novo Nordisk expand its portfolio of oral biologic pipeline assets by using Emisphere’s drug…
03 Sep 20
Parnell claims that its Nomovid is an easy-to-use and low-cost nasal spray product that can be rapidly commercialised…
13 Aug 20
TransCon CNP is an investigational long-acting drug, designed to facilitate uninterrupted exposure of CNP at safe, therapeutic levels
Analysts are torn on the potential of remdesivir as a Covid-19 vaccine after Gilead Sciences halted a trial…
19 Mar 20
Once the Fusogenix DNA vaccine formulation has been produced it will undergo preclinical testing for safety and efficiency
18 Mar 20
The vaccine programme is expected to enter clinical testing by the end of April